Antibody for detecting soluble platelet-derived growth factor receptor beta, kit and application

By developing antibodies and kits for the specific detection of soluble platelet-derived growth factor receptor β, the lack of sensitivity and specificity in existing detection methods has been solved, enabling efficient and accurate diagnosis and monitoring of diseases related to blood-brain barrier dysfunction.

CN121914271APending Publication Date: 2026-04-24SHENZHEN ANQUN BIOENGINEERING CO LTD +1
0 Cites 0 Cited by

Patent Information

Application Number
CN202512051146.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-31
Publication Date
2026-04-24

AI Technical Summary

Technical Problem

Current technologies lack methods that can detect soluble platelet-derived growth factor receptor β (sPDGFRβ) with high sensitivity and specificity, resulting in a lack of objectivity and accuracy in the diagnosis of cognitive impairment diseases related to blood-brain barrier dysfunction.

Method used

An antibody and kit for the specific detection of soluble platelet-derived growth factor receptor β were developed. The antibody was prepared by immunizing animals with a soluble platelet-derived growth factor receptor β specific antigen epitope peptide coupled with a carrier protein to prepare a polyclonal antibody. The chemiluminescence method was then used to achieve accurate quantification of sPDGFRβ in serum/plasma samples.

Benefits of technology

It achieves high sensitivity and specificity in the detection of sPDGFRβ, with good sensitivity and repeatability, and can accurately assist in the diagnosis and monitoring of blood-brain barrier dysfunction-related diseases, providing objective indicators for disease assessment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an antibody for detecting a soluble platelet-derived growth factor receptor beta, a kit and application. The antibody is prepared by coupling a soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide with a carrier protein and then immunizing an animal, and the amino acid sequence of the soluble platelet-derived growth factor receptor beta-specific antigen epitope peptide is at least one of a sequence shown as SEQ ID NO.1 and a sequence shown as SEQ ID NO.2. The antibody can specifically detect the soluble platelet-derived growth factor receptor beta, and has the advantages of high sensitivity, good specificity, good repeatability and the like; when being used for auxiliary diagnosis or illness monitoring of blood-brain barrier dysfunction related diseases, the kit has good sensitivity, specificity and repeatability, meets clinical application requirements, provides a more accurate and reliable objective index for auxiliary diagnosis, illness monitoring and prognosis evaluation of related diseases, and has important significance and clinical application value.
Need to check novelty before this filing date? Find Prior Art